Highlights

  • Conexeu has begun development of W.A.F.E.R.™, a fabricated, collagen-based scaffold designed to provide structural support across broad wound surfaces and large volumetric defects.
  • W.A.F.E.R.™ Sheet is being designed as a flexible sheet for potential use in a dry (lyophilized) state at the point of care, and to conform to broad wound surfaces.
  • W.A.F.E.R.™ Lattice is being designed as a lyophilized, three-dimensional scaffold for large volumetric defects, with the intent of allowing clinicians to shape it with a scalpel at the point of care.
  • Designed to be trimmed and shaped with a scalpel at the point of care, the two new formats complement the Company’s flowable CXU™ device candidate and are intended for evaluation in large defects.
  • Conexeu continues to target its planned FDA 510(k) submission for its flowable lead wound-care device candidate in the first calendar quarter of 2027, subject to successful completion of required testing, manufacturing activities and regulatory documentation.
Conexeu Sciences Announces Early-Stage Development of W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice, Fabricated Formats of Its Investigational CXU™ Platform
Conexeu Sciences Announces Early-Stage Development of W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice, Fabricated Formats of Its Investigational CXU™ Platform

Globenewswire